A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01)
Patent
CA 2646902
Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF.alpha. antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
L'invention concerne des procédés permettant de traiter des troubles liés à l'activité de CXCL13 qui utilisent des antagonistes de CXCL13 et, éventuellement, des antagonistes de TNF.alpha., tels que des anticorps, y compris des parties ou variants spécifiés, des polypeptides, des polynucléotides, des ARNsi, des ARNsh, des ribozymes, et des ADNzymes. Les troubles liés à l'activité de CXCL13 sont notamment des troubles inflammatoires, tels que des troubles pulmonaires, par exemple l'asthme, l'emphysème, et la MPOC, ainsi que le lupus érythémateux disséminé.
Bugelski Peter
Das Anuk
Griswold Don E.
Li Li
Liang Bailin
Centocor Inc.
Centocor Ortho Biotech Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Cxcl13 antagonists and their use for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cxcl13 antagonists and their use for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cxcl13 antagonists and their use for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1993845